SCHEMBL3713533

SCHEMBL3713533

O=C1CCc2ccc(Nc3nc(NCC(F)F)c4occc4n3)cc2N1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 18/20 0.77
JAK2 O60674 4/20 0.55
ABL1 P00519 4/20 0.55
LCK P06239 4/20 0.55
FYN P06241 4/20 0.55
RET P07949 4/20 0.55
MAPK8 P45983 4/20 0.55
TNK2 Q07912 4/20 0.55
MAP4K2 Q12851 4/20 0.55
NTRK2 Q16620 3/20 0.55
LTK P29376 3/20 0.55
PTK2 Q05397 3/20 0.55
ROCK1 Q13464 2/20 0.55
INSR P06213 2/20 0.55
MST1 P26927 2/20 0.55
STK16 O75716 2/20 0.55
KDR P35968 2/20 0.55
AURKA O14965 1/20 0.55
ROCK2 O75116 1/20 0.55
NTRK1 P04629 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1709874 0.91 SYK (0.75) SYKJAK2ABL1LCKFYN
SCHEMBL1709880 0.86 SYK (0.76) SYKJAK2ABL1LCKFYN
SCHEMBL1709859 0.86 SYK (0.71) SYKJAK2ABL1LCKFYN
SCHEMBL1709798 0.82 SYK (0.77) SYKJAK2ABL1LCKFYN
SCHEMBL1709844 0.82 SYK (0.65) SYKJAK2ABL1LCKFYN
SCHEMBL1709875 0.81 SYK (0.70) SYKJAK2ABL1LCKFYN
SCHEMBL7616303 0.81 SYK (0.55) SYKJAK2ABL1LCKFYN
SCHEMBL3705281 0.81 SYK (0.72) SYKJAK2ABL1LCKFYN
SCHEMBL3711654 0.80 SYK (0.55) SYKJAK2ABL1LCKFYN
SCHEMBL3711529 0.79 SYK (0.78) SYKJAK2ABL1LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885JAK2 218/4885ABL1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.